Raleigh Capital Management Inc. Has $486,000 Stake in Merck & Co., Inc. $MRK

Raleigh Capital Management Inc. decreased its position in Merck & Co., Inc. (NYSE:MRK) by 2.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 6,135 shares of the company’s stock after selling 165 shares during the period. Raleigh Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $486,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Little House Capital LLC grew its position in shares of Merck & Co., Inc. by 1.2% in the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after purchasing an additional 308 shares during the last quarter. Semus Wealth Partners LLC grew its position in shares of Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after purchasing an additional 382 shares during the last quarter. Longfellow Investment Management Co. LLC grew its position in shares of Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock valued at $1,739,000 after purchasing an additional 3,282 shares during the last quarter. Quilter Plc grew its position in shares of Merck & Co., Inc. by 5.6% in the first quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock valued at $105,988,000 after purchasing an additional 62,933 shares during the last quarter. Finally, Simplicity Wealth LLC grew its position in shares of Merck & Co., Inc. by 991.7% in the first quarter. Simplicity Wealth LLC now owns 33,394 shares of the company’s stock valued at $2,997,000 after purchasing an additional 30,335 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

MRK has been the topic of several research reports. Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $106.41.

Merck & Co., Inc. Trading Down 0.1%

Shares of MRK stock opened at $78.46 on Tuesday. The stock’s fifty day moving average price is $82.51 and its two-hundred day moving average price is $81.69. The company has a market cap of $195.98 billion, a PE ratio of 12.09, a P/E/G ratio of 0.81 and a beta of 0.37. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $114.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be issued a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 49.92%.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.